26 results on '"Oudard, S."'
Search Results
2. [Metastatic castration-resistant prostate cancer and PARP inhibitors: From tumor genomics to new therapeutic combinations].
- Author
-
Oudard S, Timsit MO, Maillet D, Mouillet G, Campedel L, Colomba É, Dourthe LM, Eymard JC, Gobert A, Jamet C, Joly C, Serrate C, and Ploussard G
- Abstract
Castration-resistant metastatic prostate cancer remains lethal and a therapeutic challenge. Current strategies are geared towards the personalization of treatments based on the identification of relevant molecular targets, including genomic alterations involved in tumoral processes. Among these novel targeted therapies, poly-ADP-ribose polymerase inhibitors (PARPi), by blocking the action of enzymes involved in deoxyribonucleic acid (DNA) repair, induce the destruction of cells carrying defects in homologous recombination repair, often associated with alterations in genes involved in this mechanism. Thus, determining the presence of a molecular anomaly, particularly alterations in the BRCA1/2 genes, is a prerequisite for initiating PARPi monotherapy. In patients with metastatic castration-resistant prostate cancer , around 20-30 % carry this type of mutation. In this population, single-agent studies have demonstrated PARPi ability to prolong overall survival, and to improve symptom control, including pain. Other studies are underway to assess their effectiveness in combination with other therapies, and it already appears that association with new-generation hormone therapy can further prolong radiological progression-free survival, regardless of the mutation status of the genes involved in DNA repair, indicating a synergistic action between PARPi and new-generation hormone therapy., (Copyright © 2024 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
3. Safety and efficacy of immunotherapy according to the age threshold of 80 years.
- Author
-
Mebarki S, Pamoukdjian F, Pierro M, Poisson J, Baldini C, Widad Lahlou, Taieb J, Fabre E, Canoui-Poitrine F, Oudard S, and Paillaud E
- Subjects
- Humans, Male, Middle Aged, Aged, Aged, 80 and over, Female, Retrospective Studies, Immunotherapy adverse effects, Observational Studies as Topic, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms drug therapy
- Abstract
Background: To compare safety and efficacy of ICIs among patients<80 and those ≥80 years of age., Methods: A single-center retrospective observational cohort study comparing patients<80 and ≥80 years of age matched for cancer site (lung vs others) and participation in a clinical trial., Primary Endpoint: grade ≥2 toxicity during the first three months of ICI therapy. The two groups were compared using univariate and multivariate regression., Results: Two hundred and ten consecutive patients were recruited, with the following characteristics: mean age: 66.5±16.8, 20% aged ≥80 years, 75% male, 97% ECOG-PS ≤ 2, 78% G8-index ≤ 14/17, 80% lung or kidney cancer, and 97% metastatic cancer. The grade ≥2 toxicity rate during the first three months of ICI therapy was 68%. Patients aged ≥80 years of age had a more significant (P<0.05) proportion of grade ≥2 non-hematological toxicities (64% vs 45%) than those aged<80 years: rash (14% vs 4%), arthralgia (7.1% vs 0.6%), colitis (4.7% vs 0.6%), cytolysis (7.1% vs 1.2%), gastrointestinal bleeding (2.4% vs 0%), onycholysis (2.4% vs 0%), oral mucositis (2.4% vs 0%), psoriasis (2.4% vs 0%), or other skin toxicities (25% vs 3%). Efficacy among patients ≥80 and<80 years of age was comparable., Conclusions: Although non-hematological toxicities affected 20% more patients aged ≥80 years, hematological toxicities and efficacy were comparable between patients aged ≥80 and<80 years with advanced cancer and treated with ICIs., (Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
4. [Collecting duct carcinoma and renal medullary carcinoma in the age of new therapies].
- Author
-
Guillaume Z, Allory Y, Auclin E, Gervais C, Auvray M, Rochand A, Mejean A, Audenet F, Vano YA, Oudard S, and Thibault C
- Subjects
- Humans, Drug Therapy, Combination, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell pathology, Carcinoma, Medullary drug therapy, Kidney Neoplasms drug therapy, Kidney Neoplasms pathology
- Abstract
Collecting duct carcinoma (also known as Bellini tumour) and renal medullary carcinoma are two extremely rare and aggressive renal cancers. They are both less responsive to conventional treatments used in clear cell renal carcinoma. There are very few studies evaluating their optimal management and currently, at the metastatic stage, polychemotherapy based on platinum salts remains the most widely used. The emergence of new treatments such as anti-angiogenic TKIs, immunotherapy or treatments targeting specific genetic abnormalities, opens up a new field of possibilities in the management of these cancers. The evaluation of the response to these treatments is therefore essential. In this article, we will review the status of their management and the various studies that have evaluated recent treatments in these two cancers., (Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
5. Future treatment options in metastatic clear cell renal cell carcinoma.
- Author
-
Simonaggio A, Auvray-Kuentz M, Rochand A, Thibault C, Gervais C, Oudard S, and Vano YA
- Subjects
- Humans, Programmed Cell Death 1 Receptor, Protein Kinase Inhibitors, Tumor Microenvironment, Carcinoma, Renal Cell pathology, Kidney Neoplasms pathology
- Abstract
The field of clear cell renal cell carcinoma (ccRCC) has undergone major changes in the last decade, both in terms of the understanding of the mechanisms of oncogenesis and the role of the tumor microenvironment in anti-tumor immunity, as well as in therapeutic developments. After the era of tyrosine kinase inhibitors (TKIs) targeting VEGFR and then the era of immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway, we are now entering the era of combination therapy for first-line metastatic cancer (m-ccRCC), such as combinations including a TKI and a PD-1 inhibitor or combinations of PD-1 and CTLA-4 blockers. In this extremely dynamic environment, new molecules with various mechanisms of action will appear in the very near future: immune response modulators (other ICIs, pro-inflammatory cytokines, gut microbiota modulators), new anti-angiogenic agents (new TKIs, anti-HIF-1α antibodies), agents affecting cell metabolism (glutaminase inhibitors, tryptophan regulators or adenosine A2A receptor antagonists) or epigenetic regulators (HDAC inhibitors). In parallel, new strategies are being evaluated that could rapidly change the standards of management of advanced disease, including therapeutic intensification with triple combinations or, conversely, adaptive and/or alternative de-escalation regimens (SURF trial), and biomarker-driven treatments (BIONIKK trial). The main new molecules and strategies currently being evaluated are reviewed in this article., (Copyright © 2022 Elsevier Masson SAS. Tous droits réservés.)
- Published
- 2022
- Full Text
- View/download PDF
6. Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO.
- Author
-
Thibault C, Elaidi R, Vano YA, Rouabah M, Braychenko E, Helali I, Audenet F, and Oudard S
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Transitional Cell pathology, Cisplatin therapeutic use, Doxorubicin therapeutic use, Humans, Methotrexate therapeutic use, Neoadjuvant Therapy, Neoplasm Invasiveness, Treatment Outcome, Urinary Bladder Neoplasms pathology, Vinblastine therapeutic use, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Carcinoma, Transitional Cell drug therapy, Clinical Trials, Phase II as Topic methods, Randomized Controlled Trials as Topic methods, Urinary Bladder Neoplasms drug therapy
- Abstract
Background: Neoadjuvant cisplatin-based chemotherapy (NAC) is the standard of care in localized muscle-invasive bladder cancer (MIBC). However, 60-70% of patients have residual tumor after NAC. Based on the overall response rate observed in the metastatic setting, ddMVAC is the most commonly used NAC regimen in Europe. The emergence of immune checkpoint inhibitor (ICI) in the metastatic setting raises the question if the combination of chemo plus ICI could increase the pCR rate., Methods/design: NEMIO is a French open-label randomized phase I/II trial assessing in the neoadjuvant setting the combination of ddMVAC plus durvalumab alone or with tremelimumab: 4 cycles of ddMVAC/2 weeks + 2 cycles of Durvalumab +/- Tremelimumab/4 weeks. Cystectomy is performed 4-8 weeks after the last dose of ddMVAC. Six pts will be included in each arm in a safety run-in cohort to evaluate the toxicity rate. Each arm will be expanded to a maximum of 60 pts. The primary endpoint of the safety run-in phase will be the rate of grade 3/4 treatment-related adverse events G3/4 TRAE. The primary endpoint of the phase II will be the pathological response rate and G 3/4 TRAE. Exploratory endpoints will include biomarkers of response and resistance to the combo. A total of 120 patients will be included in 15 French centers and we expect the recruitment to be completed in 2021., Discussion: NEMIO trial will assess for the first time the tolerance and the efficacy of ddMVAC regimen associated with checkpoints inhibitors as neoadjuvant treatment in localized MIBC. NCT number: NCT03549715. Registered on June 8, 2018., (Copyright © 2020 Société Française du Cancer. Publié par Elsevier Masson SAS. Tous droits réservés.)
- Published
- 2020
- Full Text
- View/download PDF
7. [Impact of molecular signatures on the choice of systemic treatment for metastatic kidney cancer].
- Author
-
Simonaggio A, Epaillard N, Elaidi R, Sun CM, Moreira M, Oudard S, and Vano YA
- Subjects
- Carcinoma, Renal Cell secondary, Clinical Decision-Making, Humans, Kidney Neoplasms pathology, Practice Guidelines as Topic, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell genetics, Kidney Neoplasms drug therapy, Kidney Neoplasms genetics
- Abstract
The standard of care for metastatic clear cell renal cell carcinoma (mccRCC) has changed dramatically over the past decades thanks to the increasing number of treatments: anti-VEGFR tyrosine kinase inhibitors (TKI), mTOR inhibitors and immune checkpoint inhibitors (ICI): anti PD(L)-1 used as monotherapy or in combination with anti CTLA-4 or anti angiogenic therapies. In the face of rising therapeutic options, the question of the therapeutic sequences arises: which treatment for which patient? Actually, there is a lack of predictive biomarkers. A greater understanding of the cancer biology and its interaction with the microenvironment has allowed the development of genomic signatures which could perhaps be used as predictive biomarker. This review will give an insight on some robust genomic signatures assessed in mccRCC and will have a closer look at BIONIKK phase II trial, which is the first trial to adapt treatments according to the molecular characteristics of the tumor in the context of mccRCC., (Copyright © 2020 Société Française du Cancer. Publié par Elsevier Masson SAS. Tous droits réservés.)
- Published
- 2020
- Full Text
- View/download PDF
8. BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.
- Author
-
Epaillard N, Simonaggio A, Elaidi R, Azzouz F, Braychenko E, Thibault C, Sun CM, Moreira M, Oudard S, and Vano YA
- Subjects
- Biomarkers, Tumor, Drug Therapy, Combination, Humans, Indazoles, Kidney Neoplasms pathology, Neoplasm Metastasis, Receptors, Vascular Endothelial Growth Factor antagonists & inhibitors, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Clinical Trials, Phase II as Topic methods, Ipilimumab administration & dosage, Kidney Neoplasms drug therapy, Nivolumab administration & dosage, Protein Kinase Inhibitors administration & dosage, Pyrimidines administration & dosage, Randomized Controlled Trials as Topic methods, Sulfonamides administration & dosage, Sunitinib administration & dosage
- Abstract
Background: The nivolumab-ipilimumab combination provides an overall response rate of 42% in first-line metastatic treatment of clear cell renal carcinoma (mccRCC). To date, there is no robust predictive biomarker of response to immune checkpoint inhibitor (ICI). In addition, severe autoimmune disorders occur more frequently with ICI combination than with ICI alone. The objective of this study is to compare the efficacy of ICI alone or in combination in patients according to tumor molecular characteristics., Methods: Using a 35-gene expression mRNA signature, patients were divided into 4 molecular groups (1 to 4). Patients in groups 1 and 4 were randomized to receive nivolumab alone (arms 1A and 4A) or nivolumab plus ipilimumab for 4 injections followed by nivolumab alone (arms 1B and 4B). Patients in groups 2 and 3 were randomized to receive nivolumab plus ipilimumab followed by nivolumab alone (arms 2B and 3B) or a tyrosine kinase inhibitor (sunitinib or pazopanib at the investigator's choice (arms 2C and 3C)). The main objective is the overall response rate by treatment and molecular group., Discussion: BIONIKK is the first trial in mccRCC to study the personalization of treatment with ICI or TKI according to tumor molecular characteristics in mccRCC. This trial is the most appropriate to prospectively identify biomarkers of response to nivolumab used alone or in combination or TKI monotherapy in patients with mccRCC. NCT02960906., (Copyright © 2020 Société Française du Cancer. Publié par Elsevier Masson SAS. Tous droits réservés.)
- Published
- 2020
- Full Text
- View/download PDF
9. Immunothérapie des cancers du rein.
- Author
-
Vano YA, Simonaggio A, Thibault C, and Oudard S
- Subjects
- Angiogenesis Inhibitors therapeutic use, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes metabolism, Carcinoma, Renal Cell blood supply, Carcinoma, Renal Cell immunology, Humans, Kidney Neoplasms blood supply, Kidney Neoplasms immunology, Neovascularization, Pathologic etiology, Programmed Cell Death 1 Receptor immunology, Tumor Microenvironment immunology, Carcinoma, Renal Cell therapy, Immunotherapy, Kidney Neoplasms therapy, Programmed Cell Death 1 Receptor antagonists & inhibitors
- Abstract
Immunotherapy for Renal Cell Carcinoma: Clear cell kidney cancer is a tumour type whose development and progression is driven by the HIF/VEGF angiogenesis pathway. Anti-angiogenic (AA) agents, particularly anti-VEGFR tyrosine kinase (TKI) inhibitors, have profoundly modified the prognosis of patients in the metastatic setting (mRCC) since their registration in 2006. At the same time, mTOR inhibitors have also brought significant benefit to patients. More recently, treatments restoring adaptive anti-tumor immunity, anti-program death 1 (anti-PD-1) checkpoint inhibitors (ICP), have in turn revolutionized the management of patients with mRCC. The multi-tumor efficacy of these ICPs proves the crucial role of anti-tumor immunity in tumor development and progression in a number of tumors including clear cell kidney tumours (ccRCC). The tumor immune microenvironment (TME) of ccRCC is known to be highly immunosuppressive. Thus ccRCCs are characterized by a strong infiltration of CD8+ T lymphocytes, frequently expressing immunological checkpoint molecules on their surface, giving them a poor prognostic feature. These characteristics partly explain the effectiveness of ICP in ccRCC and constitute a strong rationale for their further development, either at an earlier stage or in combination, particularly with AA or TKI. In this review are compiled the main clinical results of immunological checkpoint molecules alone or in combination in 1
st line or after TKI failure., (© 2018 Société Française du Cancer. Publié par Elsevier Masson SAS. Tous droits réservés.)- Published
- 2018
- Full Text
- View/download PDF
10. Immunothérapie dans les cancers de la prostate.
- Author
-
Oudard S, Thibault C, Angelergues A, Tartour E, Timsit MO, Mejean A, Michel C, and Vano Y
- Subjects
- Antibodies, Monoclonal therapeutic use, Cell Cycle Checkpoints drug effects, Humans, Immunomodulation immunology, Ipilimumab, Lenalidomide, Male, Nivolumab, Programmed Cell Death 1 Receptor antagonists & inhibitors, Prostatic Neoplasms pathology, Quinolines therapeutic use, Quinolones, Thalidomide analogs & derivatives, Thalidomide therapeutic use, Tissue Extracts therapeutic use, Vaccines, Synthetic therapeutic use, Cancer Vaccines therapeutic use, Immunotherapy methods, Prostatic Neoplasms therapy
- Abstract
Immunotherapy in Uro-Oncology: Immunotherapy is moving forward in prostate cancer. The autologous vaccine, Sipuleucel-T has been the first vaccine to be approved by FDA. First results with GVAX, tasquinimob or anti-PD-1 have been disappointing. Ipilimumab seen to be more active at an earlier stage of prostate disease. Identifying predictive factor or surrogate markers of activity of immunotherapy and which agents are clinically effective alone or in combination with others therapies such as hormonal or bone targeted therapies are warranted., (© 2016 Société Française du Cancer. Publié par Elsevier Masson SAS. Tous droits réservés.)
- Published
- 2016
- Full Text
- View/download PDF
11. [Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria].
- Author
-
Launay-Vacher V, Janus N, Beuzeboc P, Daniel C, Ray-Coquard I, Selle F, Rey JB, Jouannaud C, Spano JP, Thery JC, Morere JF, Goldwasser F, Mir O, Oudard S, Scotté F, Dorent R, Ludwig L, Deray G, and Gligorov J
- Subjects
- Adult, Aged, Analysis of Variance, Angiogenesis Inhibitors adverse effects, Bevacizumab adverse effects, Breast Neoplasms blood supply, Breast Neoplasms mortality, Creatinine blood, Female, France epidemiology, Humans, Hypertension mortality, Incidence, Kidney Function Tests, Middle Aged, Odds Ratio, Prevalence, Prognosis, Prospective Studies, Proteinuria mortality, Survival Analysis, Vascular Endothelial Growth Factors antagonists & inhibitors, Angiogenesis Inhibitors therapeutic use, Bevacizumab therapeutic use, Breast Neoplasms drug therapy, Hypertension epidemiology, Proteinuria epidemiology
- Abstract
Introduction: The potential prognostic value of hypertension and proteinuria of anti-vascular endothelial growth factor (VEGF) drugs has not been assessed in routine clinical practice so far in breast cancer. The objectives of the MARS study were to assess the prevalence of proteinuria and hypertension at baseline, their incidence under anti-VEGF treatment, and to evaluate a possible link with overall survival., Methods: Patients from 8 centres were included between 2009 and 2011 with a follow-up of 1 year. They were naive of any previous anti-VEGF treatment and planned to be started on one. The results of the group of patients with breast cancer receiving bevacizumab are presented., Results: Four hundred and two patients with breast cancer and treated with bevacizumab were included. At inclusion, hypertension prevalence was 12.4%, proteinuria 23.9%. The incidence of de novo proteinuria and hypertension during the follow-up was 61.7% and 16.8%, respectively. Among patients with de novo proteinuria, 62.2% afterwards improved/normalized. No thrombotic microangiopathy was reported. Baseline or de novo proteinuria/hypertension were not associated with overall survival in breast cancer patients treated with bevacizumab., Discussion: These results on the renovascular safety of bevacizumab in breast cancer patients showed that the prevalence of hypertension and proteinuria was high at baseline and, moreover, patients treated with bevacizumab frequently developed de novo hypertension and/or proteinuria. Finally, neither hypertension, nor proteinuria, neither at baseline, nor de novo, were associated with overall survival in our cohort of "real-life'' patients
- Published
- 2015
- Full Text
- View/download PDF
12. [Experimental program personalized care in patients with head and neck cancer].
- Author
-
Hans S, Scotte F, Hoffman C, Pelicier N, Ménard M, Badoual C, Oudard S, Housset M, and Brasnu D
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Head and Neck Neoplasms pathology, Head and Neck Neoplasms psychology, Head and Neck Neoplasms therapy, Humans, Male, Middle Aged, Nurse-Patient Relations, Oncology Nursing, Otorhinolaryngologic Neoplasms pathology, Otorhinolaryngologic Neoplasms psychology, Patient Care Team organization & administration, Professional-Family Relations, Program Evaluation, Psychiatry statistics & numerical data, Referral and Consultation statistics & numerical data, Needs Assessment organization & administration, Otorhinolaryngologic Neoplasms therapy, Patient Care Planning organization & administration, Patient-Centered Care organization & administration
- Abstract
Objective: Describe the implementation and preliminary results of the “Experimental Program Personalized care” in patients with Head and Neck cancer., Materials and Methods: After being selected a graduate nurse status, called coordination, participated in the development of forms of detection needs and concerns of patients, in collaboration with various health professionals., Results: Between January 2011 and December 2012, 200 new patients with head and neck cancer were included: 62% with advanced cancer and 38% of early stage. No patient refused to participate in this experiment. At least one consultation with a psychiatrist was necessary for 82% of patients with advanced cancer. Social problems were the second axis of the needs of patients., Conclusion: By identifying the needs of patients and organizing their support, this evaluation optimizes not only the therapeutic care for the patient but also the management of human resources within the team.
- Published
- 2014
- Full Text
- View/download PDF
13. [Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France].
- Author
-
Pouessel D, Oudard S, Gravis G, Priou F, Shen L, and Culine S
- Subjects
- Aged, Aged, 80 and over, Androgen Antagonists therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Disease-Free Survival, Docetaxel, Drug Administration Schedule, France, Humans, Male, Middle Aged, Mitoxantrone administration & dosage, Mitoxantrone adverse effects, Neutropenia chemically induced, Prednisone administration & dosage, Prednisone adverse effects, Prostatic Neoplasms mortality, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery, Taxoids administration & dosage, Taxoids adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Orchiectomy, Prostatic Neoplasms drug therapy
- Abstract
In 2010, results of the TROPIC study demonstrated that, when compared to mitxantrone, the novel taxane cabazitaxel improved median overall survival of patients with metastatic castration-resistant prostate cancer who progressed on or after docetaxel treatment. We report the data on efficacy and toxicity observed in the subgroup of patients included in the French centers. In this phase III randomized international trial, patients received prednisone and were treated with either 25 mg/m(2) cabazitaxel or 12 mg/m(2) mitoxantrone intravenously every three weeks. The primary endpoint was overall survival. The secondary endpoints included progression-free survival (PFS) and safety. Analyses were performed on the intention-to-treat population. Among the 90 patients enrolled in France, the median overall survival was 18 months for the cabazitaxel arm versus 14.3 months for the mitoxantrone arm. An improvement in PFS was also observed, with a median of 1.4 months for the mitoxatrone arm compared to a median of 2.5 months for the cabazitaxel arm. The most common grade ≥ 3 adverse events were hematologic with neutropenia, usually afebrile and digestive with 4 % of patients reporting diarrhea. These results are comparable to those reported for the overall population and the safety profile remains favorable without any toxic death related to cabazitaxel.
- Published
- 2012
- Full Text
- View/download PDF
14. [Prostate cancer and chemotherapy: standards care and perspectives].
- Author
-
Hadjarab Y and Oudard S
- Subjects
- Humans, Male, Prostatic Neoplasms pathology, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Prostatic Neoplasms drug therapy
- Abstract
Docetaxel is a reference treatment of metastatic prostate cancer castration-resistant. Until now, the different associations were studied without benefit when compared to docetaxel as monotherapy. Cabazitaxel showed efficacy in second-line in patients with progressive disease during or after docetaxel chemotherapy. Other molecules are being evaluated in second-line post-docetaxel. Abiraterone acetate is an alternative treatment to cabazitaxel in metastatic second-line resistant to castration. Predictive factors to choice treatment must be evaluated and proposed to personalize treatment in the future. Docetaxel activity was also studied in early stage of prostate cancer and seems to be promising. A cabazitaxel activity in early stage of cancer is also being evaluated.
- Published
- 2012
- Full Text
- View/download PDF
15. [Renal carcinoma: point on treatment of brain metastasis].
- Author
-
Teghom C, Giraud P, Menei P, Medioni J, Elaidi R, Combe P, and Oudard S
- Subjects
- Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents therapeutic use, Bevacizumab, Brain Neoplasms mortality, Carcinoma, Renal Cell mortality, Everolimus, Humans, Molecular Targeted Therapy methods, Prognosis, Radiosurgery methods, Receptor Protein-Tyrosine Kinases antagonists & inhibitors, Sirolimus analogs & derivatives, Sirolimus therapeutic use, Brain Neoplasms secondary, Brain Neoplasms therapy, Carcinoma, Renal Cell secondary, Carcinoma, Renal Cell therapy, Kidney Neoplasms
- Abstract
Prognosis of patients with renal carcinoma has improved since the advent of targeted therapies. These last years, due to the improvement of patients overall survival, the incidence of brain metastasis among renal carcinoma patients has increased. This worsens the prognosis of patients. The present revue aims to do a point on treatment of brain metastasis from renal carcinoma. It will address both locoregional (surgery, radiotherapy and stereotactic radiosurgery) and systemic (targeted therapies) treatments.
- Published
- 2012
- Full Text
- View/download PDF
16. [Bellini tumours].
- Author
-
Teghom C, Gachet J, Scotté F, Elaidi R, and Oudard S
- Subjects
- Angiogenesis Inhibitors therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Humans, Male, Nephrectomy, Prognosis, Carcinoma, Renal Cell mortality, Carcinoma, Renal Cell pathology, Carcinoma, Renal Cell therapy, Kidney Neoplasms mortality, Kidney Neoplasms pathology, Kidney Neoplasms therapy, Kidney Tubules, Collecting, Rare Diseases mortality, Rare Diseases pathology, Rare Diseases therapy
- Abstract
In Europe, renal tumours are 7th in frequency of men cancers. They are rare tumours in 10 to 15% of cases. Collecting ducts carcinomas or Bellini tumours, described for the first time in 1949, are a distinct clinical and pathological entity. They represented 1% of epithelial cancers. Nephrectomy is the treatment of localised cancer. Because of lack of recommendations, usually in clinical practice, treatment is similar to urothelial carcinomas treatments (gemcitabine plus platinium). A 72% of response rate of urothelial carcinoma to association of bevacizumab with platinium and gemcitabine 1st line chemotherapy in metastatic setting was reported. More, cases of responses of metastatic Bellini cancers to antiangiogenic treatments associated to chemotherapy were reported these last years. Bellini cancers have a poor prognostic. Unless the fact that this cancer is aggressive, after nephrectomy, cancer specific survival seems not to be different to those of patients with clear cells renal carcinoma and could be related to latest stage of disease in patients. The evaluation of efficacy of association of bevacizumab to chemotherapy is still going on in this association.
- Published
- 2011
- Full Text
- View/download PDF
17. [Management of side-effects of targeted therapies in renal cancer: endocrine side-effects and metabolic disorders].
- Author
-
Caron P, Gravis G, Oudard S, and Pignot G
- Abstract
Several types of endocrine complications and metabolic disorders can occur during treatment with targeted therapies: thyroid dysfunction, hyperglycaemia, hyperlipidaemia, etc. Thyroid dysfunctions are mainly observed with tyrosine kinase inhibitors (TKI), with a high frequency with sunitinib (18 to 85%) and sorafenib (21%). Hypothyroidism can be symptomatic with clinical signs including asthenia, constipation, cold intolerance, with elevated TSH and low free T 4 levels; or subclinical with non-specific clinical signs (asthenia) with TSH less than 8-10mIU/L and free T 4 normal, and often requiring supplementation with thyroid hormones. The occurrence of thyroid dysfunction does not mean that treatment with TKI must be stopped. Thyrotoxicosis, usually transient, can precede the onset of hypothyroidism during treatment with TKI. Specialist opinion from an endocrinologist should be considered with the occurrence of thyroid dysfunction. Abnormalities in the glycaemic and lipid profile are often seen with mTOR inhibitors and require monitoring before and during the treatment, as well as a specialist opinion from an endocrinologist in the event of hyperglycaemia or dyslipidaemia., (Copyright © 2011 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
18. [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
- Author
-
Barrascout E, Medioni J, Scotte F, Ayllon J, Mejean A, Cuenod CA, Tartour E, Elaidi R, and Oudard S
- Subjects
- Antibodies, Monoclonal, Humanized, Bevacizumab, Humans, Neovascularization, Pathologic drug therapy, Niacinamide analogs & derivatives, Phenylurea Compounds, Sorafenib, Sunitinib, Treatment Outcome, Angiogenesis Inhibitors therapeutic use, Antibodies, Monoclonal therapeutic use, Benzenesulfonates therapeutic use, Carcinoma, Renal Cell drug therapy, Indoles therapeutic use, Kidney Neoplasms drug therapy, Pyridines therapeutic use, Pyrroles therapeutic use
- Abstract
Renal cell carcinoma accounts for approximately 3% of all human malignancies. The use of cytokines in metastatic stage of disease has been the standard until last decades, presenting partial and short duration responses. Research on angiogenesis in renal carcinoma has brought important advances to understand tumor biology and to allow us development of new antiangiogenic drugs. Sunitinib (SUTENT), sorafenib (NEXAVAR) and bevacizumab (AVASTIN) are actually three molecules accepted to use in metastatic renal cell carcinoma (mRCC), with a good tolerability demonstrated in different studies. Clinical evidence shows sunitinib to be reference standard of care for the first-line treatment of mRCC. The use of bevacizumab in combination with interferon alfa (IFN alfa) can also be considered in this setting. Sorafenib is recommended for second-line treatment in cytokine-refractory patients, sunitinib being also accepted in this situation. Other combination of these molecules and their use as neo-adjuvant and adjuvant therapy is being evaluated and should change in the short term the management of the disease.
- Published
- 2010
- Full Text
- View/download PDF
19. [New targeted therapies in hormone-refractory prostate cancer].
- Author
-
Oudard S, Banu E, Scotte F, Beuzeboc P, Guyader C, and Medioni J
- Subjects
- Angiogenesis Inhibitors therapeutic use, Antibodies, Monoclonal therapeutic use, Boronic Acids therapeutic use, Bortezomib, Calcitriol therapeutic use, Cancer Vaccines therapeutic use, Diphosphonates therapeutic use, Docetaxel, Endothelin-1 antagonists & inhibitors, Epothilones therapeutic use, Humans, Male, Oligonucleotides, Antisense therapeutic use, Organoplatinum Compounds therapeutic use, Protease Inhibitors therapeutic use, Protein Kinase Inhibitors therapeutic use, Pyrazines therapeutic use, Taxoids therapeutic use, Antineoplastic Agents therapeutic use, Drug Resistance, Neoplasm, Prostatic Neoplasms drug therapy
- Abstract
Although the number of men presenting with metastatic prostate cancer has decreased significantly over the last several years, the death rate for those men is essentially unchanged. Effective treatments have not existed for prostate cancer progressing after androgen deprivation therapy until recently. Docetaxel based chemotherapy has demonstrated to extend patient survival in two large randomized studies. These studies have provided the impetus to combine docetaxel with novel biologic drugs to further consolidate the gains in long-term outcome. With the arrival of new therapies such as epothilone analogues, small molecule receptor tyrosine kinase inhibitors, monoclonal antibodies, bone-targeted drugs, antisense oligonucleotides, antiangiogenics drugs and endothelin receptor antagonists, the future of prostate cancer therapy appears promising.
- Published
- 2007
20. [Prostate cancer: update].
- Author
-
Oudard S, Medioni J, Scotté F, and Banu E
- Subjects
- Androgen Antagonists therapeutic use, Antineoplastic Agents therapeutic use, Cancer Vaccines therapeutic use, Clinical Trials, Phase III as Topic, Docetaxel, Extracellular Signal-Regulated MAP Kinases metabolism, Humans, Male, Neoplasms, Hormone-Dependent therapy, Prostate-Specific Antigen blood, Prostatic Neoplasms diagnosis, Prostatic Neoplasms metabolism, Proto-Oncogene Proteins c-akt metabolism, Radiotherapy methods, Receptor, ErbB-2 metabolism, Taxoids therapeutic use, Prostatic Neoplasms therapy
- Abstract
The study of mitotic transduction of the signal showed that overexpression of pAkt and reduction in pERK expression would be associated a biological relapse. For tumors T1-3 N0M0 at the high risk of local relapse after prostatectomy, an immediate radiotherapy compared with a differed radiotherapy (at the time of PSA relapse), showed a significant reduction in the rate of local relapse and an ameliorated progression free survival. The effectiveness of the docetaxel was confirmed in two phase III randomized clinical trials : TAX-327 with 3 arms compared docetaxel every 21 days, docetaxel every 7 days and mitoxantrone. All arms were prednisone-based. An increase in overall survival, PSA progression free survival, PSA response rate and a pain reduction were highlighted in the docetaxel arm every 21 days. Docetaxel obtained at the end of this study the marketing authorization in this indication and became the treatment of reference. The SWOG 99-16 study compared the docetaxel estramustine association with the same arm of reference, mitoxantrone and prednisone, with similar results. The addition of estramustine to the docetaxel seems to improve the PSA response rate and progression free survival, but with a greater embolic toxicity. The addition of an antiangiogenic agent, the thalidomide, to docetaxel, improves progression free survival and overall survival. PSA responses were observed with an inhibitor of the proteasome, the bortezomib, in monotherapy, contrary to the imatinib which in monotherapy didn't have any effectiveness. Studies in association with docetaxel are ongoing. Some biological responses were observed with a vaccine anti MUC-1 and must be confirmed on a greater series of patients. The docetaxel impact on localized disease is actually evaluated.
- Published
- 2005
21. Homophilic anchorage of brain-hexokinase to mitochondria-porins revealed by specific-peptide antibody cross recognition.
- Author
-
Oudard S, Miccoli L, Beurdeley-Thomas A, Dutrillaux B, and Poupon MF
- Subjects
- Amino Acid Sequence, Animals, Antibody Specificity, Binding Sites, Cross Reactions, Dicyclohexylcarbodiimide pharmacology, Enzyme-Linked Immunosorbent Assay, Epitopes immunology, Glycolysis, Hexokinase genetics, Hexokinase immunology, Mitochondria drug effects, Peptide Fragments immunology, Peptide Fragments metabolism, Porins immunology, Rats, Voltage-Dependent Anion Channels, Antibodies metabolism, Brain enzymology, Hexokinase metabolism, Mitochondria metabolism, Porins metabolism
- Abstract
In brain tumors the main source of energy is from glycolysis, which is initiated by hexokinase 1 (HK1), an enzyme bound to the mitochondrial porin. Disruption of HK binding greatly affects tumor cell survival. Little is known about the acceptor site of HK1. Therefore, a polyclonal antibody (Pab) directed to MIAAQLLAYYFTELK (MK) peptide, corresponding to the 15-amino acids of the N-terminal sequence of brain HK1 was obtained. Anti MK antibody (aMK-Pab)bound specifically to HK as shown by ELISA. The aMK-Pab binding to MK peptide was antibody-concentration dependent and was completely abolished by its preincubation with the peptide at 6 x 10-8 M. The aMK-Pab recognized cytosolic HK (cHK) and HK solubilized (sHK)from rat-brain mitochondrial preparations, but not the yeast HK which does not have the MK sequence. An anti-brain HK Pab (aHK-Pab) directed to purified HK recognized the MK peptide; aHK-Pab bound to MK and this binding was inhibited by preincubation of the antibody with the MK peptide. It was previously demonstrated that brain HK anchors to mitochondria porins, also designated as voltage dependent-anion channels (VDAC) via the MK sequence. A specific anti-VDAC antibody (aVDAC-Pab) which specifically bound the N and C-terminal sequences of VDACwas found to bind to c-HK, sHK and MK-coated wells and this binding was abolished by aVDACPabpreincubation with MK peptide. These data suggest that the three Pabs cross-react with an epitope present in HK and VDAC, and which was presented in the MK peptide. Comparison of alignment of HK or VDAC sequences, available in the protein data bank (PDB), did not allow putative homologues responsible for the cross-reaction to be identified, suggesting that the epitope is conformational. This, added to inhibition of mitochondria-isolated HK binding by the MK peptide,suggests that there is an homophilic-type interaction between HK and porin, through a peptidic structure represented at least in part in the MK peptide.
- Published
- 2004
22. [Bladder cancer: realities and perspectives].
- Author
-
Chrétien Y, Oudard S, and Durdux C
- Subjects
- Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cisplatin administration & dosage, Combined Modality Therapy, Cystectomy methods, Doxorubicin administration & dosage, Female, Genes, erbB-2, Humans, Male, Methotrexate administration & dosage, Neoplasm Recurrence, Local therapy, Neoplasm Staging, Radiotherapy Dosage, Urinary Bladder Neoplasms genetics, Urinary Bladder Neoplasms pathology, Vinblastine administration & dosage, Urinary Bladder Neoplasms therapy
- Abstract
Bladder cancer is an urologic common tumor after prostatic carcinoma. Treatment of bladder cancer requires an interdisdisciplinary approach, including urologist, medical oncologist and radiation oncologist. Treatment of superficial tumors is based on endovesical instillations and sometimes on radical cystectomy for pejorative recurrences. For invasive tumor, radical cystectomy is needed. At present, ileal reconstructions could be largely proposed, in men as in women, for better quality of life. For selected patients, chemoradiotherapy is a valid alternative treatment to radical cystectomy, with similar survival rates and conservation rates of functional bladder about 50-60 %. In spite of the efficacy of local treatment, almost one half of patients develop metastasis. Recently, new drugs like paclitaxel, gemcitabine or Herceptin are available to improve the management of metastatic disease.
- Published
- 2003
23. [Targeting the gene of glucose metabolism for the treatment of advanced gliomas].
- Author
-
Oudard S, Miccoli L, Dutrillaux B, and Poupon MF
- Subjects
- Brain metabolism, Brain Neoplasms genetics, Brain Neoplasms metabolism, Chromosome Deletion, Diazepam therapeutic use, Glioma genetics, Glioma metabolism, Glucose genetics, Glycolysis genetics, Hexokinase genetics, Hexokinase metabolism, Humans, Mitochondria metabolism, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Porins metabolism, Tumor Cells, Cultured drug effects, Antineoplastic Agents therapeutic use, Brain Neoplasms drug therapy, Glioma drug therapy, Glucose metabolism, Hexokinase antagonists & inhibitors, Indazoles therapeutic use, Neoplasm Proteins antagonists & inhibitors
- Abstract
Loss of chromosomes is a recurrent event in cancer. Chromosome-10 losses occur with tumor progression and characterize advanced gliomas. This chromosome carries many genes involved in glucose metabolism. Hexokinase (HK) gene is located on chromosome-10. Hexokinase enzymatic activity is decreased in glioblastomas. Hexokinase enables glucose entry into glycolysis and is critical for these highly glycolytic tumors. These enzyme is either free in the cytosol or bound to the mitochondrial outer membrane. Disturbance of HK binding to mitochondria by lonidamine led to inhibition of cells and xenografted-glioma growth. Hexokinase bind to a mitochondrial porin which involved peripheral benzodiazepine receptors. Inhibition of HK and peripheral benzodiazepine receptors by lonidamine and diazepam led to synergistic antitumoral activity in xenografted gliomas. Co-inhibition of these two receptors will lead to a decrease in glycolysis, often elevated in these tumors, without modifying energetic metabolism of normal cells.
- Published
- 1998
24. [Dose individualization for carboplatin in cancer chemotherapy].
- Author
-
Oudard S and Lauraine EP
- Subjects
- Antineoplastic Agents blood, Antineoplastic Agents pharmacokinetics, Carboplatin adverse effects, Carboplatin blood, Carboplatin pharmacokinetics, Dose-Response Relationship, Drug, Female, Humans, Male, Metabolic Clearance Rate, Models, Biological, Neoplasms drug therapy, Thrombocytopenia etiology, Antineoplastic Agents administration & dosage, Carboplatin administration & dosage
- Abstract
The aim of optimizing drug therapy for an individual patient is to maximize the likelihood of a desired therapeutic effect and to minimize the likelihood of toxicity. The excellent correlations between renal function and carboplatin total body clearance and between carboplatin area under the plasma concentration by time curve and thrombocytopenia allow calculation by Chatelut formula of carboplatin dosage.
- Published
- 1997
25. [MDR (Multiple Drug Resistant) type of resistance to chemotherapy in clinical practice].
- Author
-
Oudard S, Marie JP, and Pujade Lauraine E
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1 genetics, Animals, Calcium Channel Blockers pharmacology, Calcium Channel Blockers therapeutic use, Child, Preschool, Cyclosporine pharmacology, Cyclosporine therapeutic use, Drug Synergism, Gene Expression Regulation, Neoplastic, Humans, Immunosuppressive Agents pharmacology, Mice, Phenotype, Verapamil pharmacology, ATP Binding Cassette Transporter, Subfamily B, Member 1 metabolism, Drug Resistance, Multiple genetics, Drug Resistance, Neoplasm genetics
- Abstract
Multifactorial resistance is the main mechanism of chemotherapy failure in cancers. Multidrug resistance (MDR) is related to the expression of a 170 kDa membrane glycoprotein, the so-called P-glycoprotein (P-gp). This protein is able to extrude drugs of various structures and mechanisms out of the cytoplasm. P-gp is a pronostic value in hemopathy as well as in child sarcoma, osteosarcoma and neuroblastoma. Modulator agents of different generations are capable of inhibiting P-gp. MDR modulation is obtained in hemopathies and is associated with an eradication of the P-gp (+) cell clones. In solid tumors, clinical trials using verapamil or cyclosporin are not so convincing. It is likely that other mechanisms of resistance are responsible for tumor progression, such as the MRP system, glutathion and topoisomerases. A better knowledge of multifactorial resistance and drug synthesis counteracting these resistance mechanisms will allow to elaborate new therapeutic basis for cancer therapy.
- Published
- 1996
26. [Cancers of the kidney: multiple drug resistance].
- Author
-
Oudard S, Lizard G, Roignot P, and Poupon MF
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1, Combined Modality Therapy, Gene Expression Regulation, Neoplastic, Glutathione Transferase metabolism, Humans, Immunotherapy, Kidney Neoplasms genetics, Neoplasm Proteins metabolism, Phenotype, Carrier Proteins genetics, Drug Resistance, Kidney Neoplasms therapy, Membrane Glycoproteins genetics
- Abstract
The treatment of kidney cancers raise difficult problems. Usual treatments combining surgery, radiation therapy, chemotherapy and hormonotherapy are poorly effective. The immunotherapy gave only an objective response rate of 25% in metastatic renal cell carcinomas. Among cellular resistance mechanisms of renal carcinoma, the multi-drug resistance (MDR) phenotype and the glutathione redox cycle have been studied. The MDR is related to overexpression of a 170 kDa membrane glycoprotein, the so-called P glycoprotein (Pgp). This protein is a pump able to extrude from cytoplasm drugs with various structures and mechanisms. The Pgp is encoded by the MDR1 gene expression is very low in most of the normal tissues, except in colon, liver and kidney. In these tissues, the Pgp would ensure a detoxifying function related to cellular toxic compounds, elimination or transfer of molecules synthesized by the cells. According to the intrinsic resistance of renal carcinoma, MDR1 gene expression has been determined. Approximately, 80% of fresh kidney cancer before chemotherapy express resistance phenotype. Reversal compounds specifically inhibiting Pgp were found, such as verapamil, cyclosporin or quinidine. Unfortunately, the two first compounds give cardiac toxicity and immunosuppression, respectively. So far, clinical trials have not been demonstrating, but no biological resistance measures were determined, in parallel. According to the multifactorial resistance the association of reversals to chemotherapy should be introduced in clinical trials, in correlating clinical response to biological mechanisms of resistance.
- Published
- 1993
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.